Source - LSE Regulatory
RNS Number : 5337U
Abingdon Health PLC
03 December 2021
 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Publication of Annual Report and Accounts and Notice of Annual General Meeting

 

York, U.K. 3 December 2021: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, is pleased to announce is pleased to announce that its Annual General Meeting ('AGM') will be held on Friday 24 December at 9.30 a.m. at the offices of Abingdon Health, York Biotech Campus, Sand Hutton, York, YO41 1LZ, United Kingdom.

 

Given the continued uncertainty relating to COVID-19, shareholders are encouraged to vote by proxy in advance of the AGM or appointing the chair of the meeting as their proxy.

 

The Company's Annual Report and Accounts for the year ended 30 June 2021 together with the notice convening the AGM and related form of proxy has been sent to shareholders and is available on the Company's website www.abingdonhealth.com.

 

Enquiries:

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates, Chief Executive Officer

Via Walbrook PR

Melanie Ross, Chief Financial Officer


Christopher Hand, Non-Executive Chairman




Singer Capital Markets (Sole Broker and Nominated Adviser)

Tel: +44 (0)20 7496 3000

Shaun Dobson, Peter Steel, Alex Bond (Corporate Finance)


Tom Salvesen (Corporate Broking)




Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com

Paul McManus / Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

Alice Woodings

Mob: +44 (0)7407 804 654

 

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

 

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSBBBDDSGGDGBX
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Abingdon Health PLC (ABDX)

-0.50p (-5.13%)
delayed 16:57PM